Nisa Investment Advisors
ESPR

Nisa Investment Advisors’s Esperion Therapeutics ESPR Stock Holding History

Nisa Investment Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.65K Hold
3,054
– – ﹤0.01% 2477
2026
Q1 		$8.37K Buy
3,054
+5
+0.2% +$16 ﹤0.01% 2301
2025
Q4 		$11.3K Buy
3,049
+1,923
+171% +$6.21K ﹤0.01% 2162
2025
Q3 		$2.98K Buy
1,126
+185
+20% +$358 ﹤0.01% 2542
2025
Q2 		$926 Buy
+941
New +$942 ﹤0.01% 2750
2025
Q1 		– Sell
-973
Closed -$2.14K – 3011
2024
Q4 		$2.14K Buy
973
+430
+79% +$1K ﹤0.01% 2466
2024
Q3 		$896 Buy
+543
New +$1.1K ﹤0.01% 2605
2023
Q1 		– Sell
-3,800
Closed -$24K – 2575
2022
Q4 		$24K Sell
3,800
-74
-2% -$529 ﹤0.01% 2009
2022
Q3 		$31K Buy
3,874
+74
+2% +$508 ﹤0.01% 1910
2022
Q2 		$24K Hold
3,800
– – ﹤0.01% 1993
2022
Q1 		$18K Buy
+3,800
New +$16.3K ﹤0.01% 2074
2021
Q4 		– Sell
-405
Closed -$5K – 2269
2021
Q3 		$5K Hold
405
– – ﹤0.01% 2254
2021
Q2 		$9K Sell
405
-2,000
-83% -$48.2K ﹤0.01% 2239
2021
Q1 		$67K Hold
2,405
– – ﹤0.01% 1914
2020
Q4 		$63K Buy
2,405
+2,150
+843% +$64.4K ﹤0.01% 1919
2020
Q3 		$9K Hold
255
– – ﹤0.01% 2130
2020
Q2 		$13K Buy
255
+55
+28% +$2.3K ﹤0.01% 1861
2020
Q1 		$6K Hold
200
– – ﹤0.01% 1925
2019
Q4 		$12K Hold
200
– – ﹤0.01% 1796
2019
Q3 		$7K Buy
200
+70
+54% +$2.77K ﹤0.01% 1849
2019
Q2 		$6K Hold
130
– – ﹤0.01% 1858
2019
Q1 		$5K Hold
130
– – ﹤0.01% 1903
2018
Q4 		$6K Hold
130
– – ﹤0.01% 1762
2018
Q3 		$6K Sell
130
-130
-50% -$5.97K ﹤0.01% 1837
2018
Q2 		$10K Buy
260
+110
+73% +$5.56K ﹤0.01% 1736
2018
Q1 		$11K Sell
150
-100
-40% -$7.34K ﹤0.01% 1622
2017
Q4 		$16K Buy
+250
New +$13.5K ﹤0.01% 1598

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Nisa Investment Advisors's ESPR Position: Q2 2026 in Review

Nisa Investment Advisors held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 3,054 shares worth $9.65K. The position accounts for ﹤0.01% of the portfolio, ranked #2477.

Nisa Investment Advisors first reported a position in ESPR in Q4 2017 and has held it in 27 quarters since. The position peaked at $67K in Q1 2021. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Nisa Investment Advisors held 3,054 shares of Esperion Therapeutics worth $9.65K as of Q2 2026.
  • Nisa Investment Advisors left its Esperion Therapeutics share count unchanged in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2477 holding.
  • Nisa Investment Advisors first reported a position in Esperion Therapeutics in Q4 2017 and has held it in 27 quarters since.
  • Nisa Investment Advisors's Esperion Therapeutics position peaked at $67K in Q1 2021.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.